Drug Trial Radar · NCT07200830
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,524
Planned (sponsor's estimate)
Start
Mar 31, 2026
Primary completion
Sep 9, 2034
Study completion Sep 9, 2034
Sponsor
- Lead sponsor
- Alliance for Clinical Trials in OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard way this medication is given. This study is for patients with hormone resistant prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body. Hormone resistant prostate cancer often has many cells containing a protein called prostate-specific membrane antigen (PSMA) on their surface. The normal cells in the prostate do not normally express as much PSMA protein on their surface as cancer cells. Lutetium 177 Lu PSMA RLT binds to the PSMA protein on the tumor cells. It builds up in these cells and gives off radiation that may kill them. Typically, this medication is given at the same dose every 6 weeks for up to 6 doses. In this trial, researchers want to see if treatment following the first two doses of lutetium 177 Lu PSMA RLT can be delayed until there is evidence of disease activity. This may be an effective way to improve quality of life without decreasing lifespan in patients with advanced prostate cancer.
Conditions
- Metastatic Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
Lutetium Lu 177 Vipivotide TetraxetanDrug
Given IV
Biospecimen CollectionProcedure
Undergo blood sample collection
Patient MonitoringProcedure
Undergo PSA monitoring
Computed TomographyProcedure
Undergo CT
Bone ScanProcedure
Undergo Bone Scan
PSMA PET ScanProcedure
Undergo PSMA PET Scan
MRIProcedure
Undergo MRI
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Up to 5 years
- Quality of lifeTime frame: Up to 30 months
Locations
142 sites in 1 country. Site status is shown where the registry gives one.
Providence Alaska Medical Center
Anchorage, Alaska · Recruiting
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
UC San Diego Medical Center - Hillcrest
San Diego, California · Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
UCHealth Memorial Hospital Central
Colorado Springs, Colorado · Recruiting
Memorial Hospital North
Colorado Springs, Colorado · Recruiting
Helen F Graham Cancer Center
Newark, Delaware · Recruiting
Medical Oncology Hematology Consultants PA
Newark, Delaware · Recruiting
CTCA at Southeastern Regional Medical Center
Newnan, Georgia · Recruiting
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois · Recruiting
Decatur Memorial Hospital
Decatur, Illinois · Recruiting
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois · Recruiting
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois · Recruiting
SSM Health Good Samaritan
Mount Vernon, Illinois · Recruiting
Cancer Care Center of O'Fallon
O'Fallon, Illinois · Recruiting
HSHS Saint Elizabeth's Hospital
O'Fallon, Illinois · Recruiting
Northwestern Medicine Oak Brook
Oak Brook, Illinois · Recruiting
Northwestern Medicine Orland Park
Orland Park, Illinois · Recruiting
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois · Recruiting
Midwestern Regional Medical Center
Zion, Illinois · Recruiting
Mary Greeley Medical Center
Ames, Iowa · Recruiting
McFarland Clinic - Ames
Ames, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa · Suspended
McFarland Clinic - Boone
Boone, Iowa · Suspended
Saint Anthony Regional Hospital
Carroll, Iowa · Suspended
UI Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, Iowa · Suspended
Iowa Methodist Medical Center
Des Moines, Iowa · Recruiting
UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa · Suspended
Broadlawns Medical Center
Des Moines, Iowa · Suspended
UI Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines, Iowa · Suspended
Showing 40 of 142 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.